Afshin Dowlati
#164,025
Most Influential Person Now
Researcher
Afshin Dowlati's AcademicInfluence.com Rankings
Afshin Dowlaticomputer-science Degrees
Computer Science
#9684
World Rank
#10161
Historical Rank
Computational Linguistics
#2373
World Rank
#2396
Historical Rank
Machine Learning
#4307
World Rank
#4356
Historical Rank
Artificial Intelligence
#4658
World Rank
#4720
Historical Rank
Download Badge
Computer Science
Afshin Dowlati's Degrees
- PhD Computer Science Stanford University
- Masters Artificial Intelligence Stanford University
- Bachelors Computer Engineering University of California, Berkeley
Similar Degrees You Can Earn
Why Is Afshin Dowlati Influential?
(Suggest an Edit or Addition)Afshin Dowlati's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. (2006) (5665)
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children (2018) (1570)
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. (2015) (1280)
- Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. (1999) (894)
- Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial (2019) (836)
- Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. (2005) (622)
- Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data (2019) (485)
- Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. (2020) (416)
- A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. (2002) (416)
- A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo (2015) (412)
- Phase I Trial of Pazopanib in Patients with Advanced Cancer (2009) (393)
- Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599 (2005) (379)
- Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. (2005) (372)
- Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis. (2017) (321)
- Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non–Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab—an Eastern Cooperative Oncology Group Study (2008) (267)
- Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer (2018) (204)
- NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018. (2018) (195)
- Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. (2012) (190)
- Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. (2008) (177)
- Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. (1996) (177)
- Dual MET–EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer (2008) (170)
- Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. (2013) (170)
- A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. (2009) (168)
- Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study (2019) (159)
- Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer. (1997) (155)
- Effect of Hormone Replacement Therapy for Menopause on the Mechanical Properties of Skin (1995) (144)
- Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. (2009) (141)
- Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes? (2016) (141)
- Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial (2019) (134)
- Cardiovascular Safety Profile of Combretastatin A4 Phosphate in a Single-Dose Phase I Study in Patients with Advanced Cancer (2004) (128)
- The National Cancer Institute-American Society of Clinical Oncology Cancer Trial Accrual Symposium: summary and recommendations. (2013) (110)
- Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non–Small Cell Lung Cancer (2010) (104)
- Quantifying EGFR alterations in the lung cancer genome with nanofluidic digital PCR arrays. (2010) (101)
- Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. (2008) (100)
- A Vasculature-Targeting Regimen of Preoperative Docetaxel with or without Bevacizumab for Locally Advanced Breast Cancer: Impact on Angiogenic Biomarkers (2009) (99)
- Staging of the mediastinum: value of positron emission tomography imaging in non-small cell lung cancer. (1996) (98)
- Confirmation of Gene Expression–Based Prediction of Survival in Non–Small Cell Lung Cancer (2008) (95)
- Evaluation of pleural diseases with FDG-PET imaging: preliminary report. (1997) (91)
- Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation. (2001) (91)
- Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer (2017) (90)
- Phase I Trial of Pelvic Radiation, Weekly Cisplatin, and 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, NSC #663249) for Locally Advanced Cervical Cancer (2010) (87)
- The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers. (2017) (84)
- Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers. (2013) (82)
- Safety, tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors (2005) (73)
- Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. (2021) (70)
- Combined inhibition of epidermal growth factor receptor and JAK/STAT pathways results in greater growth inhibition in vitro than single agent therapy. (2004) (68)
- 441O Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC (2016) (67)
- Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: Safety, clinical activity, and PD-L1 expression. (2016) (67)
- Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists? (2006) (67)
- Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies. (2007) (66)
- Clinical correlation of extensive-stage small-cell lung cancer genomics. (2016) (65)
- Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance) (2017) (64)
- Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors (2019) (63)
- Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432 (2012) (62)
- Combined SCLC clinical and pathologic characteristics. (2013) (62)
- Phase II study of dasatinib (BMS-354825) in patients with metastatic adenocarcinoma of the pancreas. (2013) (61)
- Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (CE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161. (2020) (61)
- Efficacy and safety of rovalpituzumab tesirine in patients with DLL3-expressing, ≥ 3rd line small cell lung cancer: Results from the phase 2 TRINITY study (2018) (59)
- Phase I Study of Pazopanib in Patients with Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study (2013) (59)
- Phase II study of bryostatin 1 and vincristine for aggressive non‐Hodgkin lymphoma relapsing after an autologous stem cell transplant (2009) (59)
- Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT, NF-κB, and Cell-Cycle Progression in Non–Small Cell Lung Cancer (2014) (58)
- From COX-2 inhibitor nimesulide to potent anti-cancer agent: synthesis, in vitro, in vivo and pharmacokinetic evaluation. (2012) (57)
- Bronchiolitis obliterans organizing pneumonia and ulcerative colitis after allogeneic bone marrow transplantation (1998) (56)
- Bevacizumab Maintenance in Patients with Advanced Non–Small-Cell Lung Cancer, Clinical Patterns, and Outcomes in the Eastern Cooperative Oncology Group 4599 Study: Results of An Exploratory Analysis (2012) (55)
- Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK+ advanced NSCLC (aNSCLC). (2018) (55)
- Activation state EGFR and STAT-3 as prognostic markers in resected non-small cell lung cancer. (2007) (54)
- Chemotherapy in Patients ≥80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and LUN 6 (2007) (50)
- Five-year survival does not equal cure in non-small cell lung cancer: a Surveillance, Epidemiology, and End Results-based analysis of variables affecting 10- to 18-year survival. (2012) (50)
- Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors (2018) (47)
- Inflammatory Breast Cancer as a Model Disease to Study Tumor Angiogenesis: Results of a Phase IB Trial of Combination SU5416 and Doxorubicin (2007) (47)
- Synergistic killing of human small cell lung cancer cells by the Bcl-2-inositol 1,4,5-trisphosphate receptor disruptor BIRD-2 and the BH3-mimetic ABT-263 (2015) (46)
- Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma. (2008) (46)
- Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study. (2019) (46)
- Novel Phase I Dose De-escalation Design Trial to Determine the Biological Modulatory Dose of the Antiangiogenic Agent SU5416 (2005) (46)
- Safety and antitumor activity of durvalumab monotherapy in patients with pretreated extensive disease small-cell lung cancer (ED-SCLC). (2018) (44)
- A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck (2005) (44)
- Phase I and correlative study of combination bryostatin 1 and vincristine in relapsed B-cell malignancies. (2003) (43)
- Phase I Study of Pazopanib in Combination with Paclitaxel and Carboplatin Given Every 21 Days in Patients with Advanced Solid Tumors (2012) (43)
- Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors. (2010) (42)
- Toxicity of sunitinib plus bevacizumab in renal cell carcinoma. (2010) (42)
- Soluble and cell-associated transferrin receptor in lung cancer. (1997) (42)
- Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study (2019) (42)
- Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target (2018) (41)
- A phase II study of cisplatin (P) plus etoposide (E) plus bevacizumab (B) for previously untreated extensive stage small cell lung cancer (SCLC) (E3501): A trial of the Eastern Cooperative Oncology Group (2007) (40)
- RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR (2016) (40)
- Low PIAS3 Expression in Malignant Mesothelioma Is Associated with Increased STAT3 Activation and Poor Patient Survival (2014) (39)
- The Association and Nuclear Translocation of the PIAS3-STAT3 Complex Is Ligand and Time Dependent (2009) (39)
- Protein inhibitor of activated STAT3 expression in lung cancer (2011) (39)
- Prospective correlative assessment of biomarkers in E4599 randomized phase II/III trial of carboplatin and paclitaxel ± bevacizumab in advanced non-small cell lung cancer (NSCLC). (2006) (39)
- Phase II Study of the Multitargeted Tyrosine Kinase Inhibitor XL647 in Patients with Non–Small-Cell Lung Cancer (2012) (39)
- A Randomized Phase II Trial of Two Schedules of Docetaxel in Elderly or Poor Performance Status Patients with Advanced Non-small Cell Lung Cancer (2007) (38)
- A Phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma (2020) (38)
- Anaemia of lung cancer is due to impaired erythroid marrow response to erythropoietin stimulation as well as relative inadequacy of erythropoietin production (1997) (38)
- Staging of non-small-cell lung cancer by whole-body fluorine-18 deoxyglucose positron emission tomography (1996) (34)
- Phase I clinical and pharmacokinetic study of rebeccamycin analog NSC 655649 given daily for five consecutive days. (2001) (34)
- The FACT inhibitor CBL0137 Synergizes with Cisplatin in Small-Cell Lung Cancer by Increasing NOTCH1 Expression and Targeting Tumor-Initiating Cells. (2018) (34)
- Multi-institutional phase I/II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited-stage small-cell lung carcinoma. (2000) (33)
- Identification of a class of novel tubulin inhibitors. (2012) (33)
- Activity of XL647 in clinically selected NSCLC patients (pts) enriched for the presence of EGFR mutations: Results from Phase 2 (2008) (32)
- Phase-II Trial of Rebeccamycin Analog, a Dual Topoisomerase-I and -II Inhibitor, in Relapsed “Sensitive” Small Cell Lung Cancer (2012) (31)
- O-086a Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C)with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial — E4599 (2005) (31)
- Synthesis and anticancer mechanism investigation of dual Hsp27 and tubulin inhibitors. (2013) (31)
- Phase II trial of Sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer (2014) (31)
- A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus‐positive patients with cancer: AIDS Malignancy Consortium trial AMC 061 (2014) (30)
- Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy. (2007) (30)
- Abstract A49: Clinically efficacy of the BET bromodomain inhibitor TEN-010 in an open-label substudy with patients with documented NUT-midline carcinoma (NMC) (2015) (30)
- Preliminary safety results of a phase II trial comparing two schedules of lapatinib (GW572016) as first line therapy for advanced or metastatic non-small cell lung cancer (2005) (29)
- Therapeutic challenges of AIDS-related non-Hodgkin's lymphoma in the United States and East Africa. (2002) (29)
- Safety and clinical activity of durvalumab in combination with tremelimumab in extensive disease small-cell lung cancer (ED-SCLC). (2018) (29)
- Pharmacokinetics (PK) and tolerability of GW786034, a VEGFR tyrosine kinase inhibitor, after daily oral administration to patients with solid tumors. (2004) (28)
- A phase II multicenter trial comparing two schedules of lapatinib (LAP) as first or second line monotherapy in subjects with advanced or metastatic non-small cell lung cancer (NSCLC) with either bronchioloalveolar carcinoma (BAC) or no smoking history (2007) (28)
- Clinical utility of reflex testing using focused next-generation sequencing for management of patients with advanced lung adenocarcinoma (2018) (28)
- Checkpoint Kinase 1 Inhibition Enhances Cisplatin Cytotoxicity and Overcomes Cisplatin Resistance in SCLC by Promoting Mitotic Cell Death. (2019) (28)
- BRAF in Lung Cancers: Analysis of Patient Cases Reveals Recurrent BRAF Mutations, Fusions, Kinase Duplications, and Concurrent Alterations. (2018) (28)
- A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer (2016) (28)
- MA15.02 Long-Term Safety and Clinical Activity Results from a Phase Ib Study of Erlotinib Plus Atezolizumab in Advanced NSCLC (2018) (27)
- Evaluation of interleukin-6 in bronchoalveolar lavage fluid and serum of patients with lung cancer. (1999) (27)
- Retinoblastoma mutation predicts poor outcomes in advanced non small cell lung cancer (2019) (27)
- Hepatic rejection after orthotopic liver transplantation for hepatic veno-occlusive disease or graft-versus-host disease following bone marrow transplantation. (1995) (26)
- KMT2D Mutation Is Associated With Poor Prognosis in Non–Small‐Cell Lung Cancer (2018) (26)
- Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer (2000) (26)
- Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer (2014) (25)
- Phase I trial of docetaxel and thalidomide: a regimen based on metronomic therapeutic principles (2008) (24)
- Randomized phase II trial of single agent erlotinib vs. standard chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) of 2. (2006) (23)
- Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions (2017) (23)
- JASPER: Phase 2 trial of first‐line niraparib plus pembrolizumab in patients with advanced non–small cell lung cancer (2021) (23)
- Multi-institutional phase I trials of anticancer agents. (2008) (23)
- First-in-human study of REGN3767 (R3767), a human LAG-3 monoclonal antibody (mAb), ± cemiplimab in patients (pts) with advanced malignancies. (2019) (23)
- Cooperative interaction between protein inhibitor of activated signal transducer and activator of transcription‐3 with epidermal growth factor receptor blockade in lung cancer (2009) (23)
- Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non‐Hodgkin lymphoma (2009) (22)
- Updated results from a phase 1 study of AMG 757, a half-life extended bispecific T-cell engager (BiTE) immuno-oncology therapy against delta-like ligand 3 (DLL3), in small cell lung cancer (SCLC). (2021) (22)
- Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer. (2015) (22)
- Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors (2009) (22)
- A Phase II Study of Concurrent Chemoradiation with Weekly Docetaxel, Carboplatin, and Radiation Therapy Followed by Consolidation Chemotherapy with Docetaxel and Carboplatin for Locally Advanced Inoperable Non-small Cell Lung Cancer (NSCLC) (2009) (21)
- Safety and preliminary clinical activity of the MET antibody mixture, Sym015 in advanced non-small cell lung cancer (NSCLC) patients with MET amplification/exon 14 deletion (METAmp/Ex14∆). (2020) (21)
- RET Mutation and Expression in Small-Cell Lung Cancer (2014) (21)
- PIAS3 expression in squamous cell lung cancer is low and predicts overall survival (2015) (21)
- Human herpesvirus-8-associated disseminated angiosarcoma in an HIV-seronegative woman: report of a case and limited case-control virologic study in vascular tumors. (2000) (21)
- Phase I trial of three-weekly Docetaxel, Carboplatin and oral lenalidomide (Revlimid®) in patients with advanced solid tumors (2007) (20)
- CD30 Is a Potential Therapeutic Target in Malignant Mesothelioma (2015) (19)
- Clinical summary of 67 heavily pre-treated patients with metastatic carcinomas treated with GW572016 in a phase Ib study. (2004) (19)
- Dual VEGF/VEGFR inhibition in advanced solid malignancies (2014) (19)
- A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma (2009) (18)
- A multi-center, randomized, double-blind phase II study comparing temozolomide (TMZ) plus either veliparib (ABT-888), a PARP inhibitor, or placebo as 2nd or 3rd-line therapy for patients (Pts) with relapsed small cell lung cancers (SCLCs). (2016) (17)
- Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies (2014) (17)
- Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States (2021) (17)
- Pharmacogenomic Approach to Identify Drug Sensitivity in Small-Cell Lung Cancer (2014) (17)
- A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumors (2011) (17)
- SCH66336, inhibitor of protein farnesylation, blocks signal transducer and activators of transcription 3 signaling in lung cancer and interacts with a small molecule inhibitor of epidermal growth factor receptor/human epidermal growth factor receptor 2 (2008) (16)
- Author Correction: Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data (2019) (16)
- Prognostic potential of neutrophil-to-lymphocyte ratio and lymphocyte nadir in stage III non-small-cell lung cancer. (2017) (16)
- Clinical trial design in small cell lung cancer: surrogate end points and statistical evolution. (2014) (16)
- A Predictive 7-Gene Assay and Prognostic Protein Biomarkers for Non-small Cell Lung Cancer (2018) (15)
- Abstract PR13: Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions (2015) (15)
- A detailed smoking history and determination of MYC status predict response to checkpoint inhibitors in advanced non-small cell lung cancer (2020) (14)
- Phase I study of MEDI0639 in patients with advanced solid tumors. (2015) (14)
- 1530PDResults of a randomized, placebo-controlled, phase 2 study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC) (2017) (14)
- Phase I study of the combination of quinacrine and erlotinib in patients with locally advanced or metastatic non small cell lung cancer (2018) (13)
- Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC (2018) (13)
- Brief Report: A Phase 1 Study Evaluating Rovalpituzumab Tesirine (Rova-T) in Frontline Treatment of Patients With Extensive-Stage Small Cell Lung Cancer. (2021) (13)
- Chemical warfare casualties and yperite-induced xerodermoid. (1990) (13)
- Phase I study of the safety, tolerability, and pharmacokinetics (PK) of weekly paclitaxel administered in combination with pazopanib (GW786034) (2008) (13)
- Microbiome dysbiosis and epigenetic modulations in lung cancer: from pathogenesis to therapy. (2021) (13)
- LY3022855, an anti–colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial (2021) (12)
- PIGMENTARY CHANGES IN SKIN SENESCENCE (1991) (12)
- Radiosensitization of non-small-cell lung cancer cells and xenografts by the interactive effects of pemetrexed and methoxyamine. (2016) (12)
- MA11.07 Improved Small Cell Lung Cancer (SCLC) Response Rates with Veliparib and Temozolomide: Results from a Phase II Trial (2017) (12)
- Phase I clinical trial of the base excision repair inhibitor methoxyamine in combination with fludarabine for patients with advanced hematologic malignancies (2017) (12)
- PIAS3 activates the intrinsic apoptotic pathway in non‐small cell lung cancer cells independent of p53 status (2014) (12)
- Comparison of cisplatin/etoposide versus carboplatin/etoposide concurrent chemoradiation therapy for limited-stage small cell lung cancer (LS-SCLC) in the elderly population (age >65 years) using national SEER-Medicare data. (2016) (12)
- Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross‐sectional and longitudinal analysis using two large national registries (2021) (12)
- A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors (2019) (11)
- P3.02c-046 Safety, Clinical Activity and Biomarker Results from a Phase Ib Study of Erlotinib plus Atezolizumab in Advanced NSCLC: Topic: IT (2017) (11)
- Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNA (2021) (11)
- Beyond adenocarcinoma: current treatments and future directions for squamous, small cell, and rare lung cancer histologies. (2015) (11)
- Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors (2012) (11)
- Chemotherapy in patients ≥ 80 with advanced non-small cell lung cancer: combined results from SWOG 0027 and LUN 6 (2005) (11)
- Post‐transcriptional regulation of PIAS3 expression by miR‐18a in malignant mesothelioma (2018) (11)
- Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC. (2017) (11)
- Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine (2009) (11)
- A phase I study examining weekly dosing and pharmacokinetics (PK) of a novel spectrum selective kinase inhibitor, XL999, in patients (pts) with advanced solid malignancies (ASM). (2006) (10)
- Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers (2009) (10)
- Identification of STAT3-independent regulatory effects for protein inhibitor of activated STAT3 by binding to novel transcription factors (2011) (10)
- A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction (2019) (10)
- Novel Non-Invasive Radiomic Signature on CT Scans Predicts Response to Platinum-Based Chemotherapy and Is Prognostic of Overall Survival in Small Cell Lung Cancer (2021) (10)
- Hunting and trapping the vascular endothelial growth factor. (2010) (10)
- A phase 1b study to assess the safety of PLX3397, a CSF-1 receptor inhibitor, and paclitaxel in patients with advanced solid tumors. (2014) (9)
- A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors (2016) (9)
- NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types (2021) (9)
- High neuron specific enolase levels in bronchoalveolar lavage fluid of patients with lung carcinoma: Diagnostic value, relation to serum neuron specific enolase, and staging (1996) (9)
- Larotrectinib efficacy and safety in adult TRK fusion cancer patients. (2019) (9)
- Role of mTOR as an essential kinase in SCLC. (2020) (9)
- Phase I study of the safety and pharmacokinetics (PK) of paclitaxel or paclitaxel with carboplatin administered in combination with pazopanib (GW786034) (2007) (9)
- Gastrin levels in serum and bronchoalveolar lavage fluid of patients with lung cancer: comparison with patients with chronic obstructive pulmonary disease. (1996) (9)
- Comparison of power between randomized discontinuation design and upfront randomization design on progression-free survival. (2009) (9)
- Phase I Clinical Trials in Patients ≥80. (2011) (9)
- Paclitaxel added to the cisplatin/etoposide regimen in extensive-stage small cell lung cancer -- the use of complete response rate as the primary endpoint in phase II trials. (2001) (8)
- A first-in-human study of mirzotamab clezutoclax as monotherapy and in combination with taxane therapy in relapsed/refractory solid tumors: Dose escalation results. (2021) (8)
- Activity of larotrectinib in patients with TRK fusion GI malignancies. (2018) (8)
- An update of pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients (pts) with malignant pleural mesothelioma (MPM): A phase II clinical trial (2005) (8)
- Identification of RUNX1T1 as a potential epigenetic modifier in small‐cell lung cancer (2020) (8)
- Abstract CT008: Clinical safety and activity from a phase I study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions (2016) (8)
- Immunotherapy in EGFR mutant non-small cell lung cancer: when, who and how? (2019) (8)
- Small Cell Lung Cancer, Version 2.2022 (2021) (8)
- Randomized phase II trial of different schedules of administration of rebeccamycin analogue as second line therapy in non-small cell lung cancer (2005) (7)
- Phase II trial of maintenance daily oral thalidomide in patients with extensive-stage small cell lung cancer (ES-SCLC) in remission (2005) (7)
- CBL0137 increases the targeting efficacy of Rovalpituzumab tesirine against tumour-initiating cells in small cell lung cancer (2020) (7)
- A Phase I Study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer (2013) (7)
- Modulation of immunological histamine release from human lung fragments by stem cell factor, IL-3, IL-5 and GM-CSF: comparison with human leukocytes. (1994) (7)
- Is response rate relevant to the phase II trial design of targeted agents? (2008) (7)
- Phase I trials of targeted anticancer drugs: a need to refocus (2012) (7)
- Erlotinib beyond progression study: Randomized phase II study comparing chemotherapy plus erlotinib with chemotherapy alone in EGFR tyrosine kinase inhibitor (TKI)-responsive, non-small cell lung cancer (NSCLC) that subsequently progresses. (2013) (7)
- Identification of Prognostic and Chemopredictive microRNAs for Non-Small-Cell Lung Cancer by Integrating SEER-Medicare Data (2021) (7)
- Pharmacokinetic profile of the base-excision repair inhibitor methoxyamine-HCl (TRC102; MX) given as an one-hour intravenous infusion with temozolomide (TMZ) in the first-in-human phase I clinical trial. (2010) (7)
- A Phase II Trial of Carboplatin and Gemcitabine with Exisulind (IND #65,056) in Patients with Advanced Non-small Cell Lung Cancer: An Eastern Cooperative Oncology Group Study (E1501) (2006) (7)
- A randomized controlled trial of structured palliative care versus standard supportive care for patients enrolled in phase 1 clinical trials (2021) (7)
- Avelumab in patients with previously treated mesothelioma: Updated phase 1b results from the JAVELIN Solid Tumor trial. (2018) (6)
- Relationship between phase I study duration and symptom burden (2018) (6)
- Phase I trial of pomalidomide given for patients with advanced solid tumors (2012) (6)
- A phase I study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients (pts) with advanced solid tumors. (2017) (6)
- Reciprocal expression of INSM 1 and YAP 1 defines subgroups in small cell lung cancer (2017) (6)
- A brief intensive cisplatin-based outpatient chemotherapy regimen with filgrastim and megestrol acetate support for advanced non-small cell lung cancer: results of a phase II trial. (1998) (6)
- Randomized phase 3 study of the anti-disialoganglioside antibody dinutuximab and irinotecan vs irinotecan or topotecan for second-line treatment of small cell lung cancer. (2022) (6)
- 447PDPHASE IB STUDY OF PLX3397, A CSF1R INHIBITOR, AND PACLITAXEL IN PATIENTS WITH ADVANCED SOLID TUMORS. (2014) (5)
- Phase Ib study of pevonedistat , a NEDD 8-activating enzyme inhibitor , in combination with docetaxel , carboplatin and paclitaxel , or gemcitabine , in patients with advanced solid tumors (5)
- A phase I study of talotrexin (PT-523) in patients with relapsed or refractory non-small cell lung cancer (NSCLC). (2006) (5)
- Brentuximab Vedotin in Patients With CD30+ Mesothelioma (2014) (5)
- RESILIENT: Study of irinotecan liposome injection (nal-IRI) in patients with small cell lung cancer—Preliminary findings from part 1 dose-defining phase. (2019) (5)
- A PHASE 1 STUDY OF BET INHIBITION USING RG6146 IN RELAPSED/REFRACTORY (R/R) MYC‐EXPRESSING DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) (2017) (5)
- Phase 1b study of avelumab in advanced previously treated mesothelioma: long-term follow-up from JAVELIN Solid Tumor. (2018) (5)
- Role of exosomes in lung cancer: A comprehensive insight from immunomodulation to theragnostic applications. (2022) (5)
- A phase 1 study of SGN-B6A, an antibody-drug conjugate targeting integrin beta-6, in patients with advanced solid tumors (SGNB6A-001, Trial in Progress). (2021) (5)
- A Phase 1 Study Evaluating Rovalpituzumab Tesirine in Frontline Treatment of Patients With Extensive-Stage SCLC (2021) (5)
- SGN228-001: A phase I open-label dose-escalation, and expansion study of SGN-CD228A in select advanced solid tumors. (2020) (5)
- Abstract A6: Pazopanib combination with paclitaxel and carboplatin in patients with advanced solid tumors and gynecological cancers: Results of two phase I studies (2009) (5)
- 1268P JASPER: Efficacy and safety of first-line (1L) niraparib plus a programmed death receptor 1 inhibitor (PD-1i) in patients with advanced non-small cell lung cancer (NSCLC) (2020) (5)
- Frequency of NOTCH pathway mutation in primary tumor of SCLC compared to metastatic biopsies and association with better survival. (2018) (5)
- A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumours (2020) (5)
- Phase II trial of sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer (SCLC): Final results. (2012) (5)
- Next Generation Sequencing of Advanced Non-Small Cell Lung Cancer: Utilization Based on Race and Impact on Survival. (2020) (5)
- Simpson’s paradox – aggregating and partitioning populations in health disparities of lung cancer patients (2015) (5)
- Abstract B109: Oral dual PI3K/mTOR inhibitor bimiralisib demonstrates tolerability and a signal of activity in head and neck squamous cell cancer with NOTCH1 loss-of-function mutation (2019) (5)
- Role of immunotherapy in gastro‐enteropancreatic neuroendocrine neoplasms (gep‐nens): Current advances and future directions (2021) (4)
- A phase II trial of carboplatin and gemcitabine with exisulind (IND # 65,056) in patients with advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Trial 1501. (2004) (4)
- Genomic alterations in small cell lung cancer and their clinical relevance. (2016) (4)
- Epidermal hyperplasia with or without atypia in patients exposed to mustard gas. (1993) (4)
- A phase I study evaluating rovalpituzumab tesirine (ROVA-T) in frontline treatment of patients (pts) with extensive stage small cell lung cancer (ES-SCLC) (2019) (4)
- RESILIENT part 1: a phase 2 dose‐exploration and dose‐expansion study of second‐line liposomal irinotecan in adults with small cell lung cancer (2022) (4)
- Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC (2022) (4)
- Imaging features of gastrointestinal toxicity in non-small cell lung cancer patients treated with erlotinib: A single institute 13-year experience. (2020) (4)
- 359 AMG 757, a half-life extended bispecific T-cell engager (BiTE®) immune therapy against DLL3 in SCLC: phase 1 interim results (2020) (4)
- Results of a completed phase I trial of CBL0137 administered intravenously (IV) to patients (Pts) with advanced solid tumors. (2020) (4)
- High UDG and BRCA1 expression is associated with adverse outcome in patients with pemetrexed treated non-small cell lung Cancer. (2018) (4)
- Phase I study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in patients with small cell lung cancer (SCLC). (2020) (4)
- Use of CD30 expression in human malignant mesothelioma as a novel therapeutic target. (2013) (4)
- Activation state (phosphorylated) EGFR and STAT3 as prognostic markers in resected non-small cell lung cancer (NSCLC) (2005) (4)
- Phase I Trial of the Base – Excision Repair Blocker Methoxyamine (TRC-102) Combined with Fludarabine in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Lymphoid Malignancies (2014) (3)
- Modulation of tumor growth and survival pathways in cancer patients treated with GW572016 (2004) (3)
- Phase I clinical trial of temozolomide and methoxyamine (TRC-102), an inhibitor of base excision repair, in patients with advanced solid tumors (2020) (3)
- OA11.03 A Phase 1 Study of AMG 757, Half-Life Extended Bispecific T-Cell Engager (BiTE®)Immune Therapy Against DLL3, in SCLC (2021) (3)
- Abstract 1743: Phase 1 clinical trial of the base-excision repair inhibitor Methoxyamine-HCl (TRC102; MX) in combination with Temozolomide (TMZ) in patients with solid tumors (2012) (3)
- Stereotactic body radiotherapy (SBRT) for T2N0 (>3 cm) non-small cell lung cancer: Outcomes and failure patterns. (2021) (3)
- Prognostic markers in small cell lung cancer (2014) (3)
- The safety and efficacy of PEN-221 somatostatin analog (SSA)-DM1 conjugate in patients (PTS) with advanced GI mid-gut neuroendocrine tumor (NET): Phase 2 results. (2021) (3)
- Evaluating the role of phase I expansion cohorts in oncologic drug development (2017) (3)
- OA03.03 Initial Efficacy and Safety Results of Irinotecan Liposome Injection (nal-IRI) in Patients with Small Cell Lung Cancer (2019) (3)
- Diffuse Atypical Cystic Brain Metastases in ALK+ NSCLC Treated With Whole Brain Radiation and Second-Generation ALK-Targeted Therapy. (2019) (3)
- The FACT inhibitor CBL 0137 Synergizes with Cisplatin in Small-Cell Lung Cancer by Increasing NOTCH 1 Expression and Targeting Tumor-Initiating Cells (2018) (3)
- Abstract 753: Pharmacokinetic profile of the base-excision repair inhibitor methoxyamine-HCl (TRC102; MX) given as an one-hour intravenous infusion with temozolomide (TMZ) in the first in human phase 1 clinical trial (2012) (3)
- OA12.05 Phase 1 Updated Exploration and First Expansion Data for DLL3-targeted T-cell Engager Tarlatamab in Small Cell Lung Cancer (2022) (3)
- A study of rovalpituzumab tesirine in frontline treatment of patients with DLL3 expressing extensive small cell lung cancer. (2017) (3)
- Oral Combination Chemotherapy in the Management of AIDS-Related Lymphoproliferative Malignancies (2012) (3)
- 150O Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions (2016) (3)
- Interaction of Treatment and Biomarker in Advanced Non-small Cell Lung Cancer. (2017) (3)
- Pharmacokinetics and Safety of Bortezomib In Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Results of the Phase 1 National Cancer Institute Organ Dysfunction Working Group Study NCI 6432 (2010) (3)
- Clinical utility of reflex testing using focused next generation sequencing for management of patients with advanced lung adenocarcinoma. (2018) (3)
- A Pharmacokinetic and Safety Study of Trebananib, an Fc‐Fusion Peptibody, in Patients With Advanced Solid Tumors and Varying Degrees of Renal Dysfunction (2017) (3)
- Early phase I study of the PARP inhibitor veliparib (ABT-888) alone or in combination with carboplatin/paclitaxel (CP) in patients with varying degrees of hepatic or renal dysfunction: A study of the NCI-Organ Dysfunction Working Group (ODG). (2014) (3)
- Phase I clinical trial of temozolomide and methoxyamine (TRC-102) in patients with advanced solid tumors. (2015) (2)
- Enhanced Radiosensitization of Lung Adenocarcinoma Cells by Pemetrexed When Combined With Methoxyamine to Inhibit Base Excision Repair (2013) (2)
- [What is your diagnosis? Osteolytic hemangiomatosis or Gorham's disease]. (1991) (2)
- Genomic analyses of high‐grade neuroendocrine gynecological malignancies reveal a unique mutational landscape and therapeutic vulnerabilities (2020) (2)
- Comparison of positron emission tomography and computed tomography in the mediastinal and extrathoracic staging of non-small cell lung cancer (1996) (2)
- 555TiP A first-in-human trial of the integrin beta-6-targeted antibody–drug conjugate, SGN-B6A, in patients with advanced solid tumors (2021) (2)
- Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study (2020) (2)
- First-in-human phase I and pharmacological study of TAS-119, a selective Aurora A (AurA) kinase inhibitor, in patients (pts) with advanced solid tumors. (2019) (2)
- A randomized phase 2 study of a human antiplatelet-derived growth factor α (PDGFRα) monoclonal antibody (olaratumab, IMC-3G3) with paclitaxel/carboplatin or paclitaxel/carboplatin alone in previously untreated patients with advanced non-small cell lung cancer (NSCLC). (2014) (2)
- Ongoing trials with bevacizumab and other antiangiogenic agents in lung cancer. (2008) (2)
- A first-in-human study of AMG 780, an angiopoietin-1 and -2 (ANG1/2) inhibitor, in patients (pts) with advanced solid tumors. (2014) (2)
- Evaluation of O6-Benzylguanine−Potentiated Topical Carmustine for Mycosis Fungoides: A Phase 1-2 Clinical Trial (2017) (2)
- Combination chemotherapy with topotecan for non-small cell lung cancer. (2003) (2)
- Modulation of tumor growth and survival pathways in cancer patients treated with GW572016. (2004) (2)
- Phase II trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical and vaginal cancer. (2011) (2)
- A phase II study of XL647 in patients with non-small cell lung cancer (NSCLC) enriched for presence of EGFR mutations (2007) (2)
- Phase I study of sunitinib malate continuously dosed and standard-infusion gemcitabine in solid tumors (2008) (2)
- Clinical, microscopic and ultrastructural alterations due to mustard gas poisoning (1992) (2)
- Identification of RICTOR amplification as a recurrent and potentially actionable alteration in small cell lung cancer patients. (2015) (2)
- A phase 2 clinical trial of pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients with peritoneal mesothelioma (PM) (2005) (2)
- MA08.10 LUNGMAP Master Protocol (LUNGMAP): Concordance Between Plasma ctDNA and Tissue Molecular Analysis (2021) (2)
- Phase I trial of daily pomalidomide in patients with advanced solid tumors. (2010) (2)
- Chk1 inhibition enhances cisplatin cytotoxicity and overcomes cisplatin resistance in small cell lung cancer by promoting mitotic cell death (2019) (2)
- P2.12-04 Liposomal Irinotecan vs Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed On/After Platinum-Based Therapy (2018) (2)
- Immune Checkpoint Blockade Outcome in Small-Cell Lung Cancer and Its Relationship With Retinoblastoma Mutation Status and Function. (2022) (2)
- Evolution of statistical methodology and design of phase II/III clinical trials in non-small cell lung cancer (NSCLC). (2006) (1)
- Interaction of treatment and biomarker in advanced NSCLC. (2016) (1)
- OA 18.03 Genomic Profiling Reveals Hedgehog Pathway Alterations in Vismodegib Sensitive Lung Squamous Cell Carcinoma (2017) (1)
- Evaluating the role of phase I expansion cohorts in drug development. (2015) (1)
- Comparison of cisplatin- versus carboplatin-based concurrent chemoradiation for limited-stage small cell lung cancer using SEER-Medicare data. (2014) (1)
- A phase I study of etirinotecan pegol in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. (2014) (1)
- [The deleterious effects of vesicant war gases]. (1989) (1)
- Phase I trial of combination becatecarin and oxaliplatin in patients with advanced solid tumors (2007) (1)
- Phase I dose escalation study of immunoconjugate L-DOS47 in combination with pemetrexed/carboplatin in non-squamous non-small cell lung cancer (NSCLC) patients. (2020) (1)
- Establishing an Interdisciplinary Oncology Team (2006) (1)
- A randomized, controlled trial of structured palliative care versus standard supportive care for patients enrolled on phase I clinical trials. (2020) (1)
- 1668TiP Phase Ib study of AMG 757, a half-life extended bispecific T-cell engager immuno-oncology therapy, combined with AMG 404, an anti-PD-1 antibody, in patients with small cell lung cancer (SCLC) (2021) (1)
- Trends in imaging utilization for small cell lung cancer: a decision tree analysis of the NCCN guidelines. (2021) (1)
- Irinotecan-Cisplatin Therapy for Patients with Extensive-Stage Small Cell Lung Cancer: Use Patterns among American Medical Oncologists 2000–2006 (2007) (1)
- CD30 expression in non-small cell lung cancer with and without ALK gene rearrangement. (2014) (1)
- Role of radiation in extensive stage small cell lung cancer: a National Cancer Database registry analysis. (2021) (1)
- Adding Base-Excision Repair Inhibitor TRC102 to Standard Pemetrexed–Platinum–Radiation in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer: Results of a Phase I Trial (2021) (1)
- Results of stereotactic body radiation therapy (SBRT) for T2 lung cancer: Outcomes of longer term follow-up. (2017) (1)
- P68.02 Computer Extracted Morphology Features of Tumor Nuclei Predict Response to Chemotherapy and Prognostic of OS in Small Cell Lung Cancer (2021) (1)
- Phase I trial of erlotinib (E), modified FOLFOX6 (mFOLFOX6), and bevacizumab (B) as first-line therapy for metastatic colorectal cancer (MCRC) (2008) (1)
- 731 A first-in-human trial of an integrin beta-6 targeted antibody-drug conjugate (ADC), SGN-B6A, in patients with advanced solid tumors: interim results of a phase 1 study (SGNB6A-001) (2022) (1)
- 369 Clinical update of VT1021, a first-in-class CD36 and CD47 targeting immunomodulating agent, in subjects with pancreatic cancer and other solid tumors stratified by novel biomarkers (2021) (1)
- Phase II trial of becatecarin (rebeccamycin analogue) in relapsed sensitive small cell lung cancer (SCLC) (2008) (1)
- FP10.04 RESILIENT Part 1: Safety and Efficacy of Second-Line Liposomal Irinotecan in Patients with Small Cell Lung Cancer (2021) (1)
- Retinoblastoma mutation to predict poor outcomes in non-small cell lung cancer (NSCLC). (2017) (1)
- Abstract 2932: Role of P53 in the negative regulatory function of PIAS3 with STAT3 in lung cancer (2011) (1)
- 641 Incidence and risk factors for stroke associated with immune checkpoint inhibitor therapy in cancer patients using real-world clinical data (2020) (1)
- Comparing Survival in Patients With Lung Cancer With and Without a History of Common Autoimmune Disease (2022) (1)
- Multi-institutional phase I trials involve more patients and longer accrual time compared to single institution trials (2007) (1)
- MO01.39 Liposomal Irinotecan in Adults with Small Cell Lung Cancer who Progressed on Platinum-Based Therapy: Subgroup Analyses by Platinum Sensitivity (2021) (1)
- Association of MLL2 mutation positive non-small cell lung cancer with prognosis. (2017) (1)
- 1793P RESILIENT part 1: Pharmacokinetics of second-line (2L) liposomal irinotecan in patients with small cell lung cancer (SCLC) (2020) (1)
- RESILIENT part I, an open-label, safety run-in of liposomal irinotecan in adults with small cell lung cancer (SCLC) who have progressed with platinum-based first-line (1L) therapy: Subgroup analyses by platinum sensitivity. (2020) (1)
- 556TiP A phase I study of SGN-STNV, a novel antibody–drug conjugate targeting sialyl-thomsen-nouveau antigen (STn), in adults with advanced solid tumors (SGNSTNV-001) (2021) (1)
- A phase Ia/IIa trial of Sym015, a MET antibody mixture, in patients with advanced solid tumours (2019) (1)
- Defining the role of RUNX1T1 in "combined" small cell lung cancer. (2019) (1)
- Abstract 3036: Targeting FACT complex with CBL0137 to overcome acquired resistance to EGFR-TKI in lung adenocarcinoma (2016) (1)
- Combination of quantitative features from H&E biopsies and CT scans predicts response to chemotherapy and overall survival in small cell lung cancer (SCLC). (2021) (1)
- Risk factors for myocarditis associated with immune checkpoint inhibitors using real-world clinical data. (2020) (1)
- Retinoblastoma expression and targeting by CDK4/6 inhibitors in small cell lung cancer. (2022) (1)
- Comparison of Overall and Cause-Specific Survivals of Stage 3 Non-Small Cell Lung Cancer (NSCLC) Treated With Carboplatin or Cisplatin-Based Concurrent Chemoradiation Therapy Using SEER-Medicare Data (1992-2007) (2014) (1)
- Defining subgroups of small-cell lung cancer. (2014) (1)
- Controversies in multi-institutional phase I clinical trials. (2009) (1)
- P-620 An update of pemetrexed (P) plus gemcitabine (G) asfront-line chemotherapy for patients (pts) with malignant pleural mesothelioma (MPM): A phase II clinical trial (2005) (1)
- Phase I study of oxaliplatin (Ox), irinotecan (Irino), and capecitabine (Cape) in patients with solid tumors. (2004) (1)
- Erlotinib beyond progression study: Randomized phase II study comparing chemotherapy plus erlotinib with chemotherapy alone in EGFR TKI-responsive, advanced non-small cell lung cancer (NSCLC) that subsequently progresses. (2011) (1)
- Phase I trial of docetaxel, carboplatin and lenalidomide in patients with advanced solid tumors. (2006) (1)
- Effects of Rovalpituzumab Tesirine on Ventricular Repolarization in Patients With Small‐Cell Lung Cancer (2020) (1)
- 48MO Phase I study of AMG 757, a delta-like ligand 3 (DLL3) targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer (SCLC) (2021) (1)
- Corrigendum to 'Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States': [ESMO Open Volume 6, Issue 5, October 2021, 100252]. (2021) (1)
- A Pilot Study Examining the Prognostic Utility of Tumor Shrinkage on Cone-Beam Computed Tomography (CBCT) for Stage III Locally Advanced Non-Small Cell Lung Cancer Patients Treated with Definitive Chemoradiation (2021) (1)
- Effects of comprehensive genomic testing in a large non-small cell cancer NSCLC cohort: Racial and survival impacts. (2018) (0)
- Abstract A263: Combination of quinacrine and erlotinib overcomes resistance to erlotinib in non-small cell lung cancer. (2013) (0)
- Cancer Biology and Signal Transduction Quinacrine Overcomes Resistance to Erlotinib by Inhibiting FACT , NFk B , and Cell-Cycle Progression in Non – Small Cell Lung Cancer (2014) (0)
- Abstract CT253: Phase 1/2 study of the safety, pharmacokinetics, and preliminary clinical activity of BT7480 in patients with nectin-4 associated advanced malignancies (2023) (0)
- Biology of Human Tumors Low PIAS 3 Expression in Malignant Mesothelioma Is Associated with Increased STAT 3 Activation and Poor Patient Survival (2014) (0)
- A phase I study evaluating CC-4047 in patients with advanced solid tumors (2008) (0)
- Abstract B26: Phase 1b trial of investigational NEDD8-activating enzyme (NAE) inhibitor pevonedistat (TAK-924/MLN4924) in combination with docetaxel, paclitaxel/carboplatin, or gemcitabine in patients (pts) with solid tumors (2015) (0)
- A Phase 1, Open-Label, Dose-Escalation Study of L-DOS47 in Combination With Pemetrexed Plus Carboplatin in Patients With Stage IV Recurrent or Metastatic Nonsquamous NSCLC (2022) (0)
- Cross-sectional imaging utilization for EGFR, EML/ALK, and KRAS mutant non-small cell lung cancer. (2019) (0)
- Phase 1/2 study of the novel SUMOylation inhibitor TAK-981 in adult patients (pts) with advanced or metastatic solid tumors or relapsed/refractory (RR) hematologic malignancies. (2021) (0)
- Pursuing Immunotherapeutic Targets in SCLC. (2021) (0)
- Correlation of 5-year survival and cure in NSCLC: An analysis of delayed cancer deaths in long-term survivors of NSCLC. (2010) (0)
- Temporal evolution of patient characteristics enrolled on phase I trials (2011) (0)
- Abstract 2249: Induction of PIAS3 by curcumin as a novel treatment strategy in mesothelioma. (2013) (0)
- Inhibition of constitutively activated Src and STAT3 in small cell lung cancer (SCLC) results in growth inhibition. (2006) (0)
- 147P Characterizing CRS in phase I study of DLL3-targeted T cell engager tarlatamab in small cell lung cancer (2022) (0)
- Phase I pharmacokinetic trial of docetaxel and thalidomide: A regimen based on anti-angiogenic therapeutic principles. (2004) (0)
- Phase I pharmacokinetic trial of docetaxel and thalidomide: A regimen based on anti-angiogenic therapeutic principles (2004) (0)
- Abstract 2266: Molecular and genomic characterization of SCLC (2016) (0)
- Author response for "Role of immunotherapy in gastro‐enteropancreatic neuroendocrine neoplasms (gep‐nens): Current advances and future directions" (2021) (0)
- Slicing and dicing small cell lung cancer to improve trial outcomes. (2020) (0)
- Long-term outcome after high-dose 3D conformal RT for stage III NSCLC: A single-institution experience. (2011) (0)
- Genomic and transcriptomic profiles of gynecologic neuroendocrine carcinoma are distinct from pulmonary neuroendocrine small cell carcinoma. (2020) (0)
- Survival in patients with prostate cancer and history of autoimmune disease. (2022) (0)
- Final report of an open-label phase II trial of bevacizumab plus docetaxel and gemcitabine in metastatic, previously untreated nonsquamous non-small cell lung cancer (NSCLC). (2012) (0)
- Author Correction: Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data (2019) (0)
- OA01.03 Prognostic Role of NLR in Stage III NSCLC Undergoing Chemoradiation: Secondary Analysis of Proclaim Trial (2019) (0)
- Combining Pemetrexed With Methoxyamine to Enhance the Radiosensitization of Non-Small Cell Lung Cancer (NSCLC): Preclinical Studies In Vivo (2014) (0)
- Abstract 847: PIAS3 induction of apoptosis is p53-independent and has STAT3-independent mediators. (2013) (0)
- Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data (2019) (0)
- Genomic profiling of circulating tumor DNA in small cell lung cancer: comparison of relapsed disease to initial tumor biopsies. (2017) (0)
- Abstract 4182: Bioinformatic analysis identifies polo-like kinase as a therapeutic target in small-cell lung cancer (2014) (0)
- Abstract CT062: Efficacy and safety of larotrectinib in patients with cancer andNTRKgene fusions or other alterations (2020) (0)
- Tarlatamab, a first-in-class DLL3-targeted bispecific T cell engager, in recurrent small-cell lung cancer: an open-label, phase 1 study. (2023) (0)
- Multi-Institutio nal P hase I /II T rial o f P aclitaxel, Cisplatin, a nd E toposide W ith C oncurrent R adiation f or Limited-Stage S mall-Cell L ung C arcinoma (2000) (0)
- RUNX1T1 Amplification Induces Small Cell Cancer (2017) (0)
- Prophylactic Cranial Irradiation (PCI) and Consolidative Thoracic Radiation (TRT) in Extensive Stage Small Cell (ES-SCLC) Lung Cancer (2020) (0)
- Outcomes of Initial Therapy for Synchronous Brain Metastases from Extensive Stage Small Cell Lung Cancer (2020) (0)
- Perspective of hansen's disease in the islamic republic of Iran (1990) (0)
- Effect of Pevonedistat, an Investigational NEDD8‐Activating Enzyme Inhibitor, on the QTc Interval in Patients With Advanced Solid Tumors (2022) (0)
- P1.04-13 Combining Clinical and Genomic Data for Predicting Response to Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer (2018) (0)
- A phase I study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer. (2011) (0)
- Improved 4-year Overall and Local Failure-free Survival in Stage IIIA Non-small Cell Lung Cancer After High-dose, 3D Conformal RT (3DCRT) ± Chemotherapy (CT) - A Single Institution Experience (2012) (0)
- Clinical trial design in small cell lung cancer: Surrogate endpoints and statistical evolution. (2012) (0)
- Abstract 2495:RUNX1T1is amplified in combined small cell lung cancer (2018) (0)
- 374 A first-in-human Phase 1/2 open label trial evaluating the safety, pharmacology, and preliminary efficacy of VT1021 in subjects with advanced solid tumors (2020) (0)
- 161O RESILIENT part 2: A randomized, open-label phase III study of liposomal irinotecan versus topotecan in adults with relapsed small cell lung cancer (SCLC) (2023) (0)
- Development of a prognostic risk model for small cell lung cancer: Identification of high-, intermediate-, and low-risk cohorts based on clinical-genomic data. (2019) (0)
- Current and Emerging Treatment Options for Patients With Relapsed Small-cell Lung Carcinoma: A Systematic Literature Review. (2023) (0)
- HHV-8 RELATED DISSEMINATED ANGIOSARCOMA IN AN HIV-SERONEGATIVE WOMAN: REPORT OF A CASE AND LIMITED CASE-CONTROL VIROLOGIC STUDY IN VASCULAR TUMORS. (1999) (0)
- A phase II study of concurrent chemoradiotherapy with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non-small cell lung cancer (2008) (0)
- Phase I expansion study of sunitinib and bevacizumab in patients with advanced solid malignancies. (2013) (0)
- Running Title : KMT 2 D is frequently mutated in human small cell lung cancer 1 Small cell lung cancer exhibits frequent inactivating mutations in the histone methyltransferase KMT 2 D / MLL 2 : CALGB 151111 ( Alliance ) (2016) (0)
- Aids-Related Malignancies (2001) (0)
- Abstract CT055: PAVO: A phase-II, open label, single arm study of niraparib in patients with locally advanced/metastatic PALB2 mutated tumors (2023) (0)
- The Effect of Thoracic Radiation Therapy on Overall Survival in SCLC: Findings from the National Cancer Database (2019) (0)
- Radiologic imaging utilization of small cell lung cancer staging and treatment. (2019) (0)
- Mistletoe lectin inhibits growth of Myc‐amplified small‐cell lung cancer (2022) (0)
- P48.14 RESILIENT Part 2: A phase 3 Study of Liposomal Irinotecan in Patients with Small-Cell Lung Cancer in the Second-Line Setting (2021) (0)
- A phase I study of sunitinib malate (S) and gemcitabine (G) in solid tumors. (2010) (0)
- Racial differences in incidence, outcomes, and genomic alterations in small cell lung cancer. (2021) (0)
- RESILIENT part II: an open-label, randomized, phase III study of liposomal irinotecan injection in patients with small-cell lung cancer who have progressed with platinum-based first-line therapy. (2020) (0)
- Case report of three distinctive pulmonary toxicities related to durvalumab (PD-L1 inhibitor) consolidation therapy in locally advanced non-small cell lung cancer (2021) (0)
- Comparison of Overall and Cause-Specific Survivals of Stage III Non-Small Cell Lung Cancer (NSCLC) Treated With Carboplatin- or Cisplatin-Based Concurrent Chemoradiation Therapy Using SEER-Medicare Data (1992-2007): Locally Advanced Non-Small Cell Lung Cancer (2014) (0)
- Subasumstat, a first-in-class inhibitor of SUMO-activating enzyme, demonstrates dose-dependent target engagement and SUMOylation inhibition, leading to rapid activation of innate and adaptive immune responses in the dose escalation portion of a phase 1/2 clinical study (2022) (0)
- Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer. (2023) (0)
- [Basocellular epithelioma]. (1989) (0)
- Abstract 1184: The effect of dual VEGF/VEGFR inhibition on angiogenic signaling pathways. (2013) (0)
- Abstract 4490: Post-transcriptional regulation on PIAS3 expression in malignant mesothelioma (2017) (0)
- Short paper Gastrin levels in serum and bronchoalveolar lavage fluid of patients with lung cancer : comparison with patients with chronic obstructive pulmonary disease (0)
- Retrospective analysis of phase 1 study duration and symptom burden among patients at a comprehensive cancer center. (2016) (0)
- a Composite Clinical Stage For Aids-related Kaposi's Sarcoma (ks): A Refinement Of The Aids Clinical Trials Group (actg) Clinical Staging Classification. : abstract 54 (1999) (0)
- Clinical correlation of genomic mutations in small cell lung cancer. (2015) (0)
- An open-label, multicenter, phase 2 study of the safety and efficacy of navtemadlin (KRT-232) in patients with TP53 wild-type relapsed/refractory small cell lung cancer. (2022) (0)
- Survival in patients with breast cancer and history of autoimmune disease. (2022) (0)
- Blood-based early detection of malignant mesothelioma (2009) (0)
- Shifting of patient characteristics enrolled on phase I clinical trials (2008) (0)
- Investigational NEDD8-activating enzyme inhibitor pevonedistat (Pev) plus chemotherapy in patients (Pts) with solid tumors (Phase 1b study): Antitumor activity of pev plus carboplatin (Carbo)/paclitaxel (Pac). (2016) (0)
- 754 A phase 1/2 study of ASP1570 in participants with locally advanced or metastatic solid tumors who have progressed on, or are ineligible for, all available standard therapies (2022) (0)
- 83 POSTER A phase I study examining weekly weight based or fixed dosing and pharmacokinetics (PK) of a novel spectrum kinase inhibitor, XL999, in patients (pts) with advanced solid malignancies (ASM) (2006) (0)
- Abstract 2026: CHK1 inhibition synergizes with cisplatin to promote mitotic cell death via activation of caspase 2 and downregulation of E2F1 in small cell lung cancer (2017) (0)
- OTHR-15. PATIENTS WITH LIMITED STAGE SMALL CELL LUNG CANCER THAT RECUR WITH ISOLATED BRAIN METASTASES HAVE PROLONGED SURVIVAL (2019) (0)
- 536P Incidence of fractures in TRK fusion cancer patients treated with larotrectinib (2021) (0)
- NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types (2021) (0)
- Base excision repair (BER) inhibitor TRC 102 (Methoxyamine) combined with pemetrexed (PEM)-based chemo-radiation (CRT) for locally advanced non-squamous non-small cell lung cancer (NS-NSCLC): Results of a phase I trial. (2020) (0)
- Enhanced antitumor activity of erlotinib in combination with quinacrine in EGFR WT and L858R/T790M mutant NSCLC. (2014) (0)
- Erlotinib monotherapy in the treatment of advanced non-small cell lung carcinoma: A single center experience with 187 patients from 2005-2018. (2019) (0)
- Gastrin levels inserum andbronchoalveolar lavage fluid ofpatients withlungcancer: comparison withpatients withchronic obstructive pulmonary disease (1996) (0)
- Small cell lung cancer in African Americans (2007) (0)
- MA13.02 Novel Non-Invasive Radiomic Signatures Extracted from Radiographic Images can Predict Response to Systemic Treatment in Small Cell Lung Cancer (2021) (0)
- 75 POSTER Pharmacokinetic (PK)-pharmacodynamic correlation, biologic and clinical effects of GW786034 (pazopanib), a VEGF tyrosine kinase inhibitor (TKI), in patients (pts) with solid tumors (2006) (0)
- Trial in progress: Natural killer (NK) cells with TGFβ receptor I inhibitor vactosertib and IL-2 in patients with metastatic colorectal cancer or hematologic malignancies. (2023) (0)
- Multidisciplinary approach to immune related adverse events as a potential biomarker: Single institution experience in non-small cell lung cancer. (2019) (0)
- [How I explore…. HLA class II by ultrastructure in toxic epidermal necrolysis]. (2016) (0)
- Are We Doing Enough? Examining the Failure Pattern Post-SBRT in T2N0 Non–small Cell Lung Cancer Patients: Single Institution Retrospective Review (2017) (0)
- A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors (2022) (0)
- A finalized phase II report of pemetrexed (P) plus gemcitabine (G) as front-line chemotherapy for patients with peritoneal mesothelioma (PM). (2006) (0)
- Chemical Warfare and Yperite-Induced Xerodermoid (1990) (0)
- Abstract CT132: Trial in progress: A phase 1/2 study of ASP1570, a novel inhibitor of DGKζ, in participants with locally advanced or metastatic solid tumors who have progressed on, or are ineligible for, all available standard therapies (2023) (0)
- MET inhibition with and without erlotinib as treatment strategy for T790M-EGFR mediated EGFR inhibitor-resistance in H1975 lung cancer cells (2008) (0)
- FPGS expression to predict overall survival in non-small cell lung cancer patients treated with pemetrexed. (2015) (0)
- 476 First-in-human phase 1/2 study of the first-in-class SUMO-activating enzyme inhibitor TAK-981 in patients with advanced or metastatic solid tumors or relapsed/refractory lymphoma: phase 1 results (2021) (0)
- Inhibition of HER signaling induces growth arrest and apoptosis in ErbB2-driven non-small cell lung cancers (2006) (0)
- Abstract 2047: Association of retinoblastoma function with response to immuno-oncology treatment in patients with small cell lung cancer (2020) (0)
- Survival in elderly patients with breast cancer with and without autoimmune disease. (2023) (0)
- A single center's experience of phase I clinical trials: Characteristics of trials and patients. (2010) (0)
- [Cutaneous manifestations of onchocerciasis]. (1989) (0)
- 132 Racial differences in TMB measures between paired tumor/normal and tumor-only sequencing across endometrial, bladder, and non-small cell lung cancers (2022) (0)
- [Cutaneous tuberculosis, a forgotten disease?]. (1990) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Afshin Dowlati?
Afshin Dowlati is affiliated with the following schools:
- University of Liège
- University of California, Berkeley
- Yale University
- Stony Brook University
- University of Sydney
- University of Alberta
- Vanderbilt University
- Stanford University
- Case Western Reserve University
- Oregon Health & Science University
- Thomas Jefferson University
- Duke University
- University of Texas Southwestern Medical Center
